Yili Pritchett

6.7k total citations · 2 hit papers
57 papers, 4.4k citations indexed

About

Yili Pritchett is a scholar working on Pharmacology, Physiology and Oncology. According to data from OpenAlex, Yili Pritchett has authored 57 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 16 papers in Physiology and 13 papers in Oncology. Recurrent topics in Yili Pritchett's work include Pain Mechanisms and Treatments (13 papers), Botulinum Toxin and Related Neurological Disorders (9 papers) and Treatment of Major Depression (9 papers). Yili Pritchett is often cited by papers focused on Pain Mechanisms and Treatments (13 papers), Botulinum Toxin and Related Neurological Disorders (9 papers) and Treatment of Major Depression (9 papers). Yili Pritchett collaborates with scholars based in United States, United Kingdom and Canada. Yili Pritchett's co-authors include Deborah N. D’Souza, Joel Raskin, Smriti Iyengar, Joachim Wernicke, Dennis L. Andress, Fujun Wang, Τushar Garimella, Paul Audhya, D. Goldstein and Robert Lenz and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Neurology.

In The Last Decade

Yili Pritchett

57 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

2010 520 citations Dick de Zeeuw, Rajiv Agarwal et al. The Lancet profile →
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

2013 487 citations Ahmed A. Othman, Weining Robieson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yili Pritchett United States	34	1.3k	1.3k	1.1k	805	585	57	4.4k
Norman Rosenthal United States	35	810 0.6×	1.1k 0.9×	245 0.2×	822 1.0×	315 0.5×	59	4.1k
Jean Joris Belgium	36	4.4k 3.3×	870 0.7×	562 0.5×	284 0.4×	579 1.0×	163	9.1k
Tuomo Polvikoski United Kingdom	34	1.9k 1.5×	226 0.2×	1.2k 1.1×	1.5k 1.9×	251 0.4×	91	5.3k
Julien Dumurgier France	37	1.8k 1.4×	213 0.2×	512 0.5×	1.4k 1.8×	475 0.8×	127	4.3k
Raf Brouns Belgium	34	360 0.3×	248 0.2×	569 0.5×	251 0.3×	206 0.4×	105	3.7k
Roberto Ceravolo Italy	49	1.2k 0.9×	299 0.2×	4.3k 3.9×	843 1.0×	716 1.2×	275	8.2k
Linda R. White Norway	35	948 0.7×	498 0.4×	821 0.7×	796 1.0×	275 0.5×	122	3.4k
Naftali Stern Israel	44	1.7k 1.3×	401 0.3×	209 0.2×	171 0.2×	174 0.3×	261	7.1k
F. van Harskamp Netherlands	28	3.3k 2.5×	419 0.3×	869 0.8×	2.9k 3.6×	766 1.3×	46	8.2k
Virgilio Gallai Italy	40	1.3k 1.0×	263 0.2×	644 0.6×	1.8k 2.2×	187 0.3×	132	4.7k

Countries citing papers authored by Yili Pritchett

Since Specialization

Citations

This map shows the geographic impact of Yili Pritchett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yili Pritchett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yili Pritchett more than expected).

Fields of papers citing papers by Yili Pritchett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yili Pritchett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yili Pritchett. The network helps show where Yili Pritchett may publish in the future.

Co-authorship network of co-authors of Yili Pritchett

This figure shows the co-authorship network connecting the top 25 collaborators of Yili Pritchett. A scholar is included among the top collaborators of Yili Pritchett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yili Pritchett. Yili Pritchett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferrarotto, Renata, Ian C. Anderson, Balazs Medgyasszay, et al.. (2021). Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Medicine. 10(17). 5748–5756. 37 indexed citations

Hussein, Maen, Donald Richards, Ivan Sinielnikov, et al.. (2021). Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Management and Research. Volume 13. 6207–6218. 16 indexed citations

Hussein, Maen, Ivan Sinielnikov, Alexander I. Spira, et al.. (2021). MO01.42 Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-Induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions. Journal of Thoracic Oncology. 16(1). S33–S34. 1 indexed citations

Weiss, Jared, Jerome H. Goldschmidt, Zoran Andrić, et al.. (2021). Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer. 22(5). 449–460. 48 indexed citations

Webb, David J., Blai Coll, Hiddo J.L. Heerspink, et al.. (2017). Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R&D. 17(3). 441–448. 7 indexed citations

Gault, Laura M., Robert Lenz, Craig Ritchie, et al.. (2016). ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimer s Research & Therapy. 8(1). 44–44. 33 indexed citations

Gault, Laura M., Craig Ritchie, Weining Robieson, et al.. (2015). A phase 2 randomized, controlled trial of the α7 agonist ABT‐126 in mild‐to‐moderate Alzheimer's dementia. Alzheimer s & Dementia Translational Research & Clinical Interventions. 1(1). 81–90. 35 indexed citations

Pritchett, Yili, et al.. (2015). Sample Size Re-estimation Designs In Confirmatory Clinical Trials—Current State, Statistical Considerations, and Practical Guidance. Statistics in Biopharmaceutical Research. 7(4). 309–321. 22 indexed citations

Zeeuw, Dick de, Blai Coll, Dennis L. Andress, et al.. (2014). The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology. 25(5). 1083–1093. 217 indexed citations

10.

Andress, Dennis L., Blai Coll, Yili Pritchett, et al.. (2012). Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sciences. 91(13-14). 739–742. 48 indexed citations

11.

Redden, Laura, Yili Pritchett, Weining Robieson, et al.. (2011). Suicidality and divalproex sodium: analysis of controlled studies in multiple indications. Annals of General Psychiatry. 10(1). 1–1. 38 indexed citations

12.

Zeeuw, Dick de, Rajiv Agarwal, Michael Amdahl, et al.. (2010). Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet. 376(9752). 1543–1551. 520 indexed citations breakdown →

13.

Farrar, John T., Yili Pritchett, Michael J. Robinson, Apurva Prakash, & Amy S. Chappell. (2009). The Clinical Importance of Changes in the 0 to 10 Numeric Rating Scale for Worst, Least, and Average Pain Intensity: Analyses of Data from Clinical Trials of Duloxetine in Pain Disorders. Journal of Pain. 11(2). 109–118. 205 indexed citations

14.

Trivedi, Madhukar H., et al.. (2008). Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. International Clinical Psychopharmacology. 23(3). 161–169. 49 indexed citations

15.

Thase, Michael E., et al.. (2007). Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychopharmacology. 27(6). 672–676. 90 indexed citations

16.

Wernicke, Joachim, Fujun Wang, Yili Pritchett, et al.. (2007). An Open-Label 52-Week Clinical Extension Comparing Duloxetine with Routine Care in Patients with Diabetic Peripheral Neuropathic Pain. Pain Medicine. 8(6). 503–513. 39 indexed citations

17.

Raskin, Joel, Fujun Wang, Yili Pritchett, & D. Goldstein. (2006). Duloxetine for Patients with Diabetic Peripheral Neuropathic Pain: A 6-Month Open-Label Safety Study. Pain Medicine. 7(5). 373–385. 73 indexed citations

18.

Wernicke, Joachim, Joel Raskin, A. Rosen, et al.. (2006). Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Current Therapeutic Research. 67(5). 283–304. 21 indexed citations

19.

Arnold, Lesley M., A. Rosen, Yili Pritchett, et al.. (2005). A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 119(1-3). 5–15. 360 indexed citations

20.

Raskin, Joel, Yili Pritchett, Fujun Wang, et al.. (2005). A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain. Pain Medicine. 6(5). 346–356. 413 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact